The European Commission has awarded a €6 million project grant to a consortium led by Professor Martin Leahy of the Tissue Optics and Microcirculation Imaging (TOMI) group at NUI Galway to develop a novel imaging platform for regenerative medicine. This new project, ‘STARSTEM’ will allow researchers and eventually, hospital doctors, to detect and measure the healing effects of novel stem cell therapies, even where they occur under the skin.
Regenerative medicine and stem cell therapies provide unique opportunities for treating a wide range of human diseases. While clinical trials have shown very promising results, scientists do not yet fully understand how stem cells trigger healing, or indeed where the cells go after they are administered to the patient. This uncertainty makes it difficult for regulators to approve new stem cell therapies, and for doctors to prescribe them.
The new STARSTEM project will address both of these challenges. Therapeutic stem cells will be ‘tagged’ with tiny gold star-shaped nanoparticles (‘nanostars’) invented at NUI Galway, which will make them much easier to detect with an exciting new imaging technology, optoacoustic imaging (OAI). This will enable researchers to track the location of very small amounts of stem cells, after they are administered. The effects of the stem cell therapy will also be measurable using OAI, which can detect healing as it happens, by measuring oxygen levels in the blood, formation of new blood vessels, and other signs of healing. These new insights will greatly help to take regenerative medicine into the clinic, a key aim of the Regenerative Medicine Institute (REMEDI) at NUI Galway.
While STARSTEM is focused on developing new imaging technologies, it opens the door to new clinical research in regenerative medicine, with new tools and capabilities, and so helps to unlock the promise of regenerative medicine. Initially using osteoarthritis as its model disease target, STARSTEM’s platform has the potential to advance new treatments for cancers, neurodegenerative diseases and a host of other illnesses.
Professor Martin Leahy, Coordinator of STARSTEM and the Director of TOMI at NUI Galway, said: “This is an exciting opportunity to use fundamental advances in the physics of imaging to validate stem cell treatments for arthritis. Once demonstrated in this application the STARSTEM technology can be used to enable a wide range of stem cell therapies.”
Professor Frank Barry, Scientific Director of REMEDI at NUI Galway, said: “It is critically important that we understand dynamics and distribution of stem cells so that we can optimise treatments for patients. This project will allow us to make great strides in this regard.”
STARSTEM brings together leaders in the nano-materials, regenerative medicine, and bio-imaging fields from across Europe. The team includes; NUI Galway (Project Co-ordinator); Technical University of Munich; University of Genoa; University of Cambridge; The Institute of Photonic Sciences, Barcelona; iThera Medical GmbH; Biorigen Srl; and Pintail Ltd, Ireland.
STARSTEM has received funding from the European Union’s Horizon 2020 research and innovation programme.